Clenbuterol is a long-acting β2-adrenergic agonist. At therapeutic doses it is β2-selective, driving cAMP elevation in bronchial smooth muscle (the veterinary indication) and in adipose and skeletal muscle (the reason it is used off-label for body-recomposition protocols). Selectivity is not absolute — at supra-therapeutic doses β1 crossover produces cardiac effects that are the dominant safety concern.
Pharmacokinetics that matter for titration
Clenbuterol has a serum half-life of 24–36 hours in humans. This is substantially longer than most users assume and has two consequences: (1) steady-state takes 5–7 days at a fixed dose, which is why subjective effects intensify across the first week at a given mg; (2) dose changes take 48–72 hours to fully manifest, meaning rapid titration escalation overshoots before the previous step has been properly assessed.
Titration schedule
40 mcg tablets split cleanly for precise titration at the start:
Days 1–2: 20 mcg once daily, morning dose only.
Days 3–4: 40 mcg morning.
Days 5–6: 60 mcg morning.
Days 7+: Plateau between 60–100 mcg depending on tolerance.
Ceiling in published research protocols: 100–120 mcg/day for adult men. Above this the β1 crossover produces disabling tremor, sleep disruption, and the cardiac symptoms that drive clen-related emergency presentations. There is no anabolic or fat-loss benefit at 140 mcg versus 100 mcg that justifies the risk increment.
Dose-response markers — the body tells you where you are
On-target presentation:
- Fine hand tremor visible when holding a glass. Tolerable; disappears with activity.
- Resting heart rate 10–15 bpm above baseline.
- Core temperature elevation 0.3–0.5 °C; light perspiration at rest.
- Mild appetite suppression; not anorexia.
Over-dose presentation — reduce dose by 20 mcg, reassess 48 hours:
- Resting heart rate >100 bpm.
- Palpitations, awareness of heartbeat, skipped beats.
- Severe insomnia across 3+ consecutive nights.
- Muscle cramping severe enough to disrupt sleep.
- Anxiety, jitters, or chest tightness at rest.
Any presentation of chest pain, dyspnea at rest, or irregular pulse is an immediate clinical evaluation — discontinue, present to A&E, disclose the exposure. Clenbuterol-induced arrhythmia and apical cardiomyopathy are documented in the emergency medicine literature at doses users routinely self-administer.
Cofactor depletion — the cramping mechanism
β2-agonism drives potassium from extracellular to intracellular compartment via Na+/K+ ATPase activation. Serum potassium falls; skeletal muscle excitability changes; cramping results. Taurine depletion compounds the picture — taurine is a calcium-handling osmolyte that clen depletes through both increased sweating and intracellular flux changes.
Supplementation:
- Taurine 3–5 g/day — resolves the majority of cramping cases within 72 hours of initiation.
- Potassium 1–2 g/day from food (banana, potato, tomato, spinach) or supplementation if cramping persists. Do not exceed 3 g/day supplemental KCl without clinical monitoring — hyperkalaemia is a worse problem than hypokalaemia.
- Magnesium 400 mg/day — general cardiovascular and neuromuscular support.
Cycling protocols — and the ketotifen mechanism
β2 receptors downregulate with sustained agonism. Peak fat-loss response occurs in the first 1–2 weeks of a given dose; thereafter the subjective effect diminishes despite continued administration.
Two protocol families address this:
- 2-on/2-off cycling. Two weeks of use followed by two weeks off. The off-phase allows β2 receptor resensitisation. Straightforward; loses the fat-loss window during off-weeks.
- Continuous use with ketotifen. Ketotifen fumarate 2 mg at night is an H1 antihistamine with documented β2 receptor upregulation as a secondary pharmacological effect — mechanism involves reduced phosphorylation of the receptor, slowing desensitisation. Allows 4–6 week continuous runs at stable dose.
Continuous use beyond 6 weeks is not supported regardless of ketotifen co-administration. The concern is cardiac: sustained β1/β2 cross-stimulation produces measurable left-ventricular hypertrophy in animal models at clen doses and durations that approximate human use. Reversibility of this remodelling is partial at best.
The cleaner alternative — salbutamol
Salbutamol (albuterol) has superior β2-selectivity (9–12× over β1 versus clen’s 4–5×) and a much shorter half-life (4–6 hours). Oral salbutamol 4 mg 3× daily produces comparable fat-loss effect to clen 80 mcg/day with substantially lower cardiac liability. It is widely overlooked in the AAS community because clen is more established by convention, not because the pharmacology favours clen.
Absolute contraindications
Do not initiate clenbuterol in the presence of:
- Pre-existing cardiomyopathy, known arrhythmia, or cardiac conduction abnormality.
- Uncontrolled hypertension (BP >140/90 untreated).
- Hyperthyroidism — exogenous β2-agonism stacked on endogenous thyroid-driven sympathetic tone is additive, not substitutive.
- Concurrent use of MAO inhibitors or tricyclic antidepressants.
- Pregnancy or breastfeeding (pharmacokinetics cross placental and mammary barriers).
The risk-benefit for clen does not work in these populations. Alternative protocols — T3 at sub-suppressive dose, caloric deficit, exercise-driven fat loss — produce outcomes within tolerable deviation from clen-assisted cuts at substantially lower cardiac risk.